Remove Pharmaceutical Companies Remove Pharmaceuticals Remove Therapies Remove Trials
article thumbnail

The killer instinct: Using investigational natural killer therapy to treat Alzheimer’s

Drug Discovery World

DDW Editor Reece Armstrong speaks to Dr Paul Song , MD, NKGen and Dr Vince DeOrchis , clinician, to find out more about the investigational natural killer therapy SNK01 and the benefit of using a patient’s own cells to treat Alzheimer’s. PS : Most, if not all, current therapies are focused on MCI. RA: How does SNK01 work?

Therapies 306
article thumbnail

Trends in Pharmaceutical Mergers and Acquisitions

DrugBank

Deal Structuring Deal structuring in pharmaceutical M&A requires a balance of financial, legal, and strategic considerations. Intellectual Property Valuation Valuing intellectual property (IP) assets is a critical component of pharmaceutical M&A, as these assets often represent a significant portion of a company's value.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Medicinal cannabis: Why more clinical trials and better access is needed

Drug Discovery World

Michael Sassano , CEO at SOMAÍ Pharmaceuticals looks at what’s needed throughout Europe to help increase access to medicinal cannabis and the current state of pharmaceutical research in this area. However, the potential use of cannabis in a pharmaceutical setting is vast. The GW Pharmaceuticals purchase by Jazz for $6.7

article thumbnail

Targeted breast cancer drug extends lives of patients in Phase III trial

Drug Discovery World

A new type of targeted medicine has shown ‘remarkable’ benefits for patients with advanced breast cancer in a major Phase III clinical trial. . The drug capivasertib combined with hormone therapy doubled the time it took for cancer to progress in people with advanced forms of the most common type of breast cancer. . months to 7.2

Trials 130
article thumbnail

Janssen seeks EU approval of new indication for CAR-T therapy

Drug Discovery World

The Janssen Pharmaceutical Companies of Johnson & Johnson have submitted a Type II variation application to the European Medicines Agency (EMA) seeking approval of Carvykti (ciltacabtagene autoleucel; cilta-cel) for relapsed and lenalidomide-refractory multiple myeloma.

Therapies 130
article thumbnail

Mathematical model can speed up Alzheimer’s drug development

Drug Discovery World

Researchers have created a mathematical model that can accurately depict Alzheimer’s disease progression in individual patients, paving the way for personalised treatment and faster development of therapies. These findings closely matched the results of the corresponding real-life clinical trials.

article thumbnail

Bios launches biotech hub to support life science progress

Drug Discovery World

The Bios Innovation Circle is aimed at empowering the success of biotech and life science companies, investors, pharmaceutical companies, clinical research organisations and other innovative solution providers to accelerate development and bring life-saving treatments to the market faster.

Science 130